CRISPR Gene Editing Market: Current Analysis and Forecast (2022-2028)

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing is a revolutionary new technology that allows scientists to precisely modify genes in living organisms. This technology has the potential to revolutionize the field of medicine and provide new treatments for a range of diseases and medical conditions, including genetic disorders, cancer, and infectious diseases. The market for CRISPR gene editing is growing rapidly, driven by the increasing demand for new and effective treatments for various diseases and conditions, as well as the growing interest in precision medicine and personalized treatments. The market is also being driven by advancements in the technology itself, which are making it increasingly accessible and cost-effective for researchers and companies to use.

The CRISPR gene editing market is expected to grow at a steady rate of around 18% owing to the growing need for novel therapeutics. The CRISPR gene editing market is highly competitive, with many established players and new entrants. Key players in the market include Editas Medicine, CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences. These companies offer a range of CRISPR gene editing products and services, including research and development, clinical trials, and commercialization. For instance, in October 2020, CRISPR Therapeutics announced the launch of a new gene-editing program for the treatment of inherited retinal diseases (IRDs). The program aims to use CRISPR-Cas9 gene editing to target and correct mutations in the genes responsible for IRDs, which can cause blindness

Based on product type, the market is segmented into CRISPR products and CRISPR services. Among these, the CRISPR products category is to witness higher CAGR during the forecast period owing to the rising demand for genetic engineering technologies, and the development of a large number of cutting-edge technologies, including CRISPR gene editing kits. Additionally, the availability of enhanced individual products that can be used to achieve a variety of goals, such as simpler gene knockouts, selective genome cleavage, less off-target cutting, genome engineering, and higher specificity, is accountable for the growth of this segment.

On the basis of application, the market is categorized into agricultural, biomedical (gene therapy, drug discovery, and diagnostics), industrial, and others. Among these, the biomedical category held a significant share of the market in 2021. The biomedical industry has been one of the earliest adopters of CRISPR gene editing technology. This is because technology has the potential to revolutionize the treatment of genetic disorders and diseases. Furthermore, growing investment in research and development in CRISPR gene editing technology, early adoption, and strict regulatory standards has made the biomedical category a key driver in the growth of the segment.

Based on end-user, the CRISPR gene editing market has been classified into academic institutes & research centers, biotechnology companies, contract research organizations (CROs), and pharmaceutical & biopharmaceutical companies. The pharmaceutical & biopharmaceutical companies category is expected to dominate the CRISPR gene editing market during the forecast period. This is mainly due to expertise in drug development, including the preclinical and clinical phases, large investment in research and development to develop new therapies, including CRISPR-based treatments, they have the necessary expertise in regulatory compliance, manufacturing, commercialization to successfully launch new CRISPR-based therapies, and pharmaceutical and biopharmaceutical companies have established distribution networks that can boost the growth of this segment.

For a better understanding of the market adoption of the CRISPR gene editing industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the region having a well-developed healthcare infrastructure and a highly skilled workforce, providing a conducive environment for the development and commercialization of CRISPR gene editing technology. The region's strong research ecosystem, including many renowned academic and research institutions, also contributes to the growth of the CRISPR gene editing market in North America.

Some of the major players operating in the market include: CRISPR Therapeutics; Thermo Fisher Scientific Inc.; Synthego; System Biosciences, LLC; ToolGen, Inc.; Agilent Technologies, Inc.; Merck KGaA; Applied StemCell; GeneCopoeia, Inc.; Cellecta, Inc